drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
An HPV-16–targeted therapeutic mRNA vaccine delivered intramuscularly that encodes HPV-16 antigens to drive intracellular antigen expression, dendritic cell activation, MHC I/II presentation, and robust HPV-16–specific CD8+ and CD4+ T-cell immunity to eliminate HPV-16–infected dysplastic and cancer cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
RNA Vaccines
drug_category
mRNA VACCINE
drug_class
Vaccine
drug_delivery_route
Intramuscular
drug_mechanism_of_action
Intramuscular mRNA delivery encoding HPV-16 antigens leads to in situ antigen expression in host antigen-presenting cells, dendritic cell activation, and MHC I/II presentation, inducing robust HPV-16–specific CD8+ cytotoxic and CD4+ helper T-cell responses that eliminate HPV-16–infected dysplastic and cancer cells.
drug_name
NWRD09
nct_id_drug_ref
NCT07092007